J Oncol Pharm Pract 2020 Jan 06
PARP-inhibitor potpourri: A comparative review of class safety, efficacy, and cost.
Related Questions
New answer by at Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center (April 16, 2020)
This is an interesting question, for which I don't have a quick answer.When it comes to PARP inhibitors (PARPi), there is compelling data for its use as maintenance therapy as...